News

The approved drug is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and above, as well as children between six to

The new facility will help Minaris support its worldwide cell and gene therapy growth. It is designed to facilitate the technology transfer of commercial advanced therapies into Europe.

Turbine noted that laboratory models often fail to capture the molecular diversity and biological complexity of many solid tumours found in patients. This limitation hampers the development of

VT3989 is a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor to target the Hippo pathway by inhibiting the palmitoylation of TEAD protein family members. Vivace Therapeutics president and

This collaboration is said to result in a “scalable” cGMP production process for DTx’s AAV-based gene therapy candidate targeting open angle glaucoma. As part of this partnership, Northway

This designation is granted for treatments that could significantly improve upon existing options. The FDA’s decision is expected by the fourth quarter of 2025, in line with the

This updated vaccine is aimed at individuals aged six months and older. The CHMP’s endorsement is based on a comprehensive body of evidence, including clinical, non-clinical, and real-world

This approval follows the previous US Food and Drug Administration (FDA) recognitions, including orphan drug and fast track designations awarded in April 2024 and December 2023 to CAN-2409

This steroid-free, topical pan-Janus kinase (JAK) inhibitor is a new option for patients who have not responded adequately to other treatments or cannot use topical corticosteroids. Anzupgo works